Full Breakdown
Heidi Overton’s FDA Nomination Faces Scrutiny Over Abortion-Pill and Vaccine Policies
By Drooid · · How we work
Confirmation Hearing Overview
President Donald Trump’s nominee, Dr. Heidi Overton, will appear before the Senate Health, Education, Labor and Pensions (HELP) Committee on Thursday to answer questions about her stance on the abortion medication mifepristone, childhood-vaccine schedules, and broader FDA priorities. The hearing comes as Senate Republican chair Sen. Bill Cassidy (R-LA) pushes the agency to reverse a Biden-era rule that permits mifepristone to be prescribed via telemedicine and mailed to patients.
Background & Context
Overton, a preventive-medicine physician, currently serves as deputy director of the White House Domestic Policy Council. Before that she was chief policy officer at the conservative think tank America First Policy Institute, where she praised the 2022 Supreme Court decision overturning Roe v. Wade and advocated “strict restrictions on medication abortion.” She also helped craft the administration’s executive order to reduce the routine childhood-vaccine schedule and split the measles-mumps-rubella (MMR) vaccine into separate shots.
The FDA has been without a permanent commissioner since Dr. Marty Makary resigned in May 2026 amid disputes over flavored-vape authorizations. Acting commissioner Kyle Diamantas has overseen a staff reduction that eliminated roughly 3,500 positions in April 2025 and a further loss of more than 3,000 employees over the past year, raising concerns about the agency’s capacity to manage food-borne illness outbreaks and product reviews.
Data & Statistics
- Staff reductions: ~3,500 layoffs in April 2025 plus an additional >3,000 departures since then.
- Food safety: A cyclospora outbreak linked to iceberg lettuce sickened >12,000 people across multiple states this summer.
- FDA safety review: The agency launched a new safety study on mifepristone in June 2026.
- Legislative deadline: The agency must update a federal court on its mifepristone review by October 7.
Official Statements & Responses
Former acting commissioner Dr.
Sen. Cassidy has repeatedly asked Overton to acknowledge that President Trump’s claim that the measles vaccine is lethal is “absurd.” He framed the hearing as a test of whether the nominee will challenge vaccine misinformation if confirmed.
Criticism & Opposition
Democratic Women’s Caucus Chairwoman Teresa Leger Fernández called the nomination “extremist” and urged colleagues to reject it, citing Overton’s “publicly denied scientific fact” on abortion-pill safety.
Verbatim Quotes
- “After the experience of the past 18 months, it’s very important to restore public and industry confidence that decisions being made by FDA, including those by leadership, are science-based, transparent and consistent,” — Dr. Stephen Ostroff, a former acting FDA commissioner
- “I think this is a key moment for the integrity of the F.D.A.,” — Dr. Joshua Sharfstein, a former principal deputy commissioner of the F
What’s Next
The HELP Committee will vote on Overthanking Overton after the Thursday hearing; a favorable committee vote is required before the full Senate considers the nomination. Regardless of the outcome, the FDA must file its progress report on the mifepristone safety review by the October 7 deadline.